Supporting efficacy and scaling with a next-generation T cell AOF formulation medium
Jul
23
2024
Upcoming webinar

Supporting efficacy and scaling with a next-generation T cell AOF formulation medium

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Supporting efficacy and scaling with a next-generation T cell AOF formulation medium

The complex manufacturing process of immune-based therapies consists of many steps, including T cell isolation, activation, genetic modification, and expansion. Precise control over the composition and source of components used in cell culture media is critical for each of these steps, which highlights a need for an enhanced formulation that can support all parts of the process. The medium should also help maintain less differentiated naive state since this subset population displays an enhanced functionality and self-renewal capacity in both diseased and non-diseased donors. Therefore, a cell culture medium that supports expansion of T cells with early memory phenotype could improve the clinical outcome of emerging immunotherapies.

This webinar will highlight a novel, next-generation medium with an animal component-free formulation developed to help increase therapeutic potential and to support the cell therapy industry’s need for consistent, reproducible, and automated T cell manufacturing.

  • How a new AOF formulation medium can support robust expansion of gene-edited early phenotype cells.
  • How a next-generation medium performs in expanding healthy and disease state donor cells.
  • Scaling and performance across culture vessels.
  • Maintaining cellular functionality throughout expansion.
Alan Gutowski
Alan Gutowski
Product Manager at Thermo Fisher Scientific

Alan Gutowski is a Product Manager at Thermo Fisher Scientific. He is responsible for the global CTS OpTmizer SFM portfolio, including the recently launched novel formulation of CTS OpTmizer One SFM. He is dedicated to helping manufacturers alleviate pain points in their workflow, across scale and modality, to bring potentially curative cell therapies to market. Alan holds degrees in Biological Sciences and Business from the University of Buffalo.

Joanna Kern
Joanna Kern
Staff Scientist at Thermo Fisher Scientific

Joanna Kern is a Staff Scientist at Thermo Fisher Scientific. She currently works on the new product introduction for Cell Therapy. Joanna has a PhD in Immunology and over 10 years of experience studying T cell biology and using flow cytometry. She is currently focused on solving challenges in the cell therapy field.